Drug intelligence / Profile preview

OPT-500

Development stage: Preclinical
Lead developer: Oppilotech
Modality: Small Molecules

Overview

OPT-500 is a preclinical-stage antibacterial small molecule being developed by Oppilotech in collaboration with Evariste. It is designed to treat infections caused by Gram-negative bacteria by targeting the isoprenoid biosynthesis pathway. This pathway is essential for the production of various critical cellular components in bacteria, and its inhibition leads to bacterial cell death. The compound was discovered using Oppilotech's proprietary systems biology platform, which utilizes high-resolution computational models of bacterial metabolism to identify and validate novel drug targets.

Targets

Non-mevalonate pathway (Methylerythritol phosphate pathway)

Beyond the preview

Go deeper on OPT-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPT-500.

Explore the full profile